DEL MAR, CA--(Marketwired - Nov 19, 2013) - The passing of the Drug Quality and Security Act (DQSA) yesterday by the US Senate is a critical and necessary move for large US drug compounders to eliminate drug mislabeling and counterfeit. The traceability legislation raises US standards for drug compounding compliance to improve consumer safety.

Frequentz, a global leader in real-time track and trace technology, has reviewed the bill, which introduces oversight by the Federal Drug Administration (FDA) for compounded drugs. The bill also expands safety and security along the entire drug development and distribution lifecycle through a track-and-trace system. Frequentz pinpoints that the bill opens traceability to a new facet of supply chain security for large volume drug compounders. This emerging facet is an opportunity that introduces traceability to the labs where compounding is performed to develop a drug as well as develop formulation.

According to Frequentz, the DQSA has marginal to no impact on the overall global traceability requirements and planning efforts. The US lags in the development of traceability regulations vis-à-vis vital economic regions where laws and regulations have already been piloted, if not fully executed abroad. However, global compliance is a key driver to the adoption of traceability solutions realized with the passing of the DQSA.

Michael Lucas, Frequentz's President and CEO is available for comment. Please contact frequentz@lewispr.com / 619-677-2700 to schedule a briefing. For more information about Frequentz's comprehensive traceability and information management technologies, visit www.frequentz.com.